Lynx1 Capital Management LP is an SEC-registered investment adviser based in Dorado, PR that reports managing 1 hedge fund on Form ADV. It reports $626.7 million in regulatory assets under management. Its private funds, of all types, hold $576.8 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +51.0% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +73.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $626.7 millionForm ADV Item 5.F
- Gross assets of private funds
- $576.8 millionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- 5Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 310301
- Latest Form ADV
- 10/07/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +33.9% | +14.8% |
| Q1 2026 | +12.8% | -4.6% |
| Q4 2025 | +11.0% | +2.4% |
| Q3 2025 | +49.4% | +7.8% |
| Q2 2025 | +17.0% | +10.4% |
| Q1 2025 | -18.2% | -4.5% |
| Q4 2024 | -17.5% | +2.1% |
| Q3 2024 | -12.3% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 31 share positions ($646,092,908) reported by Lynx1 Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- GH Research PLC48.20%
- Cullinan Therapeutics Inc21.30%
- Stoke Therapeutics Inc15.68%
- C4 Therapeutics Inc3.88%
- Precision Biosciences Inc2.67%
- Agios Pharmaceuticals Inc2.43%
- Korro Bio Inc2.37%
- Neuphoria Therapeutics Inc0.48%
- Passage Bio Inc0.47%
- Proqr Thrapeutics N V0.40%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| GH Research PLC | $311,422,002 | 48.20% | 13,263,288 | Unchanged |
| Cullinan Therapeutics Inc | $137,589,725 | 21.30% | 8,963,500 | Unchanged |
| Stoke Therapeutics Inc | $101,300,394 | 15.68% | 3,896,169 | -3.52% |
| C4 Therapeutics Inc | $25,077,947 | 3.88% | 7,530,915 | +2.79% |
| Precision Biosciences Inc | $17,266,426 | 2.67% | 2,758,215 | +190.20% |
| Agios Pharmaceuticals Inc | $15,714,150 | 2.43% | 472,606 | -86.14% |
| Korro Bio Inc | $15,310,752 | 2.37% | 1,544,980 | +0.43% |
| Neuphoria Therapeutics Inc | $3,116,168 | 0.48% | 875,328 | Unchanged |
| Passage Bio Inc | $3,031,914 | 0.47% | 673,759 | Unchanged |
| Proqr Thrapeutics N V | $2,593,074 | 0.40% | 1,562,093 | +199.59% |
| Tscan Therapeutics Inc | $2,522,022 | 0.39% | 8,019,148 | Unchanged |
| Kazia Therapeutics LTD | $2,166,551 | 0.34% | 225,800 | New |
| Pliant Therapeutics Inc | $1,941,916 | 0.30% | 1,798,070 | Unchanged |
| Entrada Therapeutics Inc | $1,769,148 | 0.27% | 278,606 | +55.99% |
| Surrozen Inc | $643,600 | 0.10% | 20,000 | New |
| Immatics N.V | $625,689 | 0.10% | 71,263 | +206.69% |
| Werewolf Therapeutics Inc | $606,676 | 0.09% | 657,786 | Unchanged |
| Yarrow Bioscience Inc | $495,440 | 0.08% | 22,000 | New |
| Xencor Inc | $453,940 | 0.07% | 18,194 | Unchanged |
| Immunocore Hldgs PLC | $433,147 | 0.07% | 14,300 | New |
| Dyne Therapeutics Inc | $402,750 | 0.06% | 25,000 | New |
| Traws Pharma Inc | $332,213 | 0.05% | 559,470 | Unchanged |
| Denali Therapeutics Inc | $240,971 | 0.04% | 11,658 | Unchanged |
| Absci Corporation | $228,809 | 0.04% | 21,245 | Unchanged |
| Foghorn Therapeutics Inc | $219,869 | 0.03% | 61,588 | Unchanged |
| Avalo Therapeutics Inc | $154,833 | 0.02% | 10,100 | Unchanged |
| Prime Medicine Inc | $137,475 | 0.02% | 45,000 | New |
| Bolt Biotherapeutics Inc | $113,344 | 0.02% | 30,800 | Unchanged |
| Eupraxia Pharmaceuticals Inc | $91,000 | 0.01% | 10,000 | Unchanged |
| Nuvation Bio Inc | $89,762 | 0.01% | 16,029 | Unchanged |
| Inhibikase Therapeutics Inc | $1,201 | 0.00% | 20,000 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 6 new positions, 2 sold out, 6 increased, 2 reduced and 17 unchanged.
Number of positions (a count, not dollars)
- New positions6
- Increased6
- Unchanged17
- Reduced2
- Sold out2
New positions
| Stock | Value | Shares |
|---|---|---|
| Kazia Therapeutics LTD | $2,166,551 | 225,800 |
| Surrozen Inc | $643,600 | 20,000 |
| Yarrow Bioscience Inc | $495,440 | 22,000 |
| Immunocore Hldgs PLC | $433,147 | 14,300 |
| Dyne Therapeutics Inc | $402,750 | 25,000 |
| Prime Medicine Inc | $137,475 | 45,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| CG Oncology Inc | $2,230,331 | 31,391 |
| Vyne Therapeutics Inc | $1,059,795 | 1,628,700 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Precision Biosciences Inc | +1,807,749 | +190.20% | $17,266,426 | 2,758,215 |
| Proqr Thrapeutics N V | +1,040,680 | +199.59% | $2,593,074 | 1,562,093 |
| C4 Therapeutics Inc | +204,224 | +2.79% | $25,077,947 | 7,530,915 |
| Entrada Therapeutics Inc | +100,000 | +55.99% | $1,769,148 | 278,606 |
| Immatics N.V | +48,027 | +206.69% | $625,689 | 71,263 |
| Korro Bio Inc | +6,684 | +0.43% | $15,310,752 | 1,544,980 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Agios Pharmaceuticals Inc | -2,936,331 | -86.14% | $15,714,150 | 472,606 |
| Stoke Therapeutics Inc | -142,235 | -3.52% | $101,300,394 | 3,896,169 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Precision Biosciences Inc | 13G amendment | 9.9% | 2,758,215 | Nov 16, 2026 | SEC.gov ↗ |
| Agios Pharmaceuticals, Inc. | 13G amendment | 0.8% | 472,606 | Nov 16, 2026 | SEC.gov ↗ |
| TScan Therapeutics, Inc. | 13G amendment | 13.1% | 20,519,148 | Aug 14, 2026 | SEC.gov ↗ |
| Stoke Therapeutics, Inc. | 13G amendment | 6.5% | 4,038,404 | Aug 14, 2026 | SEC.gov ↗ |
| C4 Therapeutics, Inc. | 13G amendment | 9.99% | 15,423,691 | Aug 14, 2026 | SEC.gov ↗ |
| iBio, Inc. | 13G | 5.4% | 2,807,016 | Aug 14, 2026 | SEC.gov ↗ |
| GH Research PLC | 13G amendment | 19.3% | 13,263,288 | Aug 14, 2026 | SEC.gov ↗ |
| Passage BIO, Inc. | 13D | 21% | 673,759 | Jul 2, 2026 | SEC.gov ↗ |
| Allogene Therapeutics, Inc. | 13G amendment | 0% | 0 | May 15, 2026 | SEC.gov ↗ |
| Korro Bio, Inc. | 13G amendment | 10.7% | 1,538,296 | Apr 2, 2026 | SEC.gov ↗ |
| Neuphoria Therapeutics Inc. | 13D amendment | 16.3% | 875,328 | Dec 29, 2025 | SEC.gov ↗ |
| Cullinan Therapeutics, Inc. | 13G amendment | 9.8% | 5,766,090 | Nov 14, 2025 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Aug 7, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures